Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
出版年份 2017 全文链接
标题
Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
作者
关键词
-
出版物
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 57, Issue -, Pages S26-S42
出版商
Wiley
发表日期
2017-09-18
DOI
10.1002/jcph.990
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
- (2017) Yuh-Min Chen Journal of the Chinese Medical Association
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitors for cancer treatment
- (2016) Junsik Park et al. ARCHIVES OF PHARMACAL RESEARCH
- Drug Development of Therapeutic Monoclonal Antibodies
- (2016) Diane R. Mould et al. BIODRUGS
- Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab
- (2016) Shruti Agrawal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy
- (2016) L. Nie et al. CLINICAL CANCER RESEARCH
- Quantitative Systems Pharmacology: A Case for Disease Models
- (2016) CJ Musante et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- An FDA oncology analysis of immune activating products and first-in-human dose selection
- (2016) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
- (2016) Anshu Kuriakose et al. Journal of Immunology Research
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective
- (2015) Yow-Ming C. Wang et al. AAPS Journal
- Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
- (2015) J. R. Sachs et al. CLINICAL CANCER RESEARCH
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- 203 Population pharmacokinetics of MEDI4736, a fully human antiprogrammed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors
- (2015) X. Song et al. EUROPEAN JOURNAL OF CANCER
- Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy
- (2015) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations
- (2014) G. Shankar et al. AAPS Journal
- Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
- (2014) Yan Feng et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop
- (2013) Jane R. Kenny et al. AAPS Journal
- Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis
- (2013) Brian J Schmidt et al. BMC BIOINFORMATICS
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions
- (2013) Andrew T. Chow et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical pharmacology considerations in biologics development
- (2012) Liang Zhao et al. ACTA PHARMACOLOGICA SINICA
- A Guide to Rational Dosing of Monoclonal Antibodies
- (2012) Shuang Bai et al. CLINICAL PHARMACOKINETICS
- Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
- (2012) Rong Deng et al. Expert Opinion on Drug Metabolism & Toxicology
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Protein–Drug Interactions and Implications for Drug Development
- (2010) S-M Huang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
- (2009) Diane D. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started